• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    10 Health Care Stocks Whale Activity In Today's Session

    6/4/24 1:35:21 PM ET
    $ABT
    $BMRN
    $BSX
    $CERE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABT alert in real time by email

    This whale alert can help traders discover the next big trading opportunities.

    Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

    Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels.

    Here's the list of options activity happening in today's session:

    Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume
    CERE PUT TRADE NEUTRAL 07/19/24 $40.00 $56.0K 3 2.9K
    LFMD CALL SWEEP BULLISH 11/15/24 $7.50 $54.4K 2.3K 836
    INCY CALL TRADE BEARISH 06/21/24 $60.00 $57.5K 6.3K 664
    ABT CALL SWEEP BULLISH 08/16/24 $110.00 $43.0K 3.0K 362
    NVAX PUT TRADE BULLISH 07/19/24 $30.00 $378.0K 308 303
    EXAS PUT SWEEP BULLISH 06/21/24 $47.50 $29.4K 1.5K 181
    BMRN PUT TRADE BEARISH 01/17/25 $75.00 $32.3K 525 68
    DXCM PUT TRADE BULLISH 12/20/24 $115.00 $33.9K 20 32
    VKTX CALL SWEEP BULLISH 01/17/25 $30.00 $66.0K 1.2K 26
    BSX CALL SWEEP BULLISH 06/21/24 $60.00 $31.9K 2.8K 20

    Explanation

    These itemized elaborations have been created using the accompanying table.

    • Regarding CERE (NASDAQ:CERE), we observe a put option trade with neutral sentiment. It expires in 45 day(s) on July 19, 2024. Parties traded 400 contract(s) at a $40.00 strike. The total cost received by the writing party (or parties) was $56.0K, with a price of $140.0 per contract. There were 3 open contracts at this strike prior to today, and today 2910 contract(s) were bought and sold.

    • For LFMD (NASDAQ:LFMD), we notice a call option sweep that happens to be bullish, expiring in 164 day(s) on November 15, 2024. This event was a transfer of 389 contract(s) at a $7.50 strike. This particular call needed to be split into 13 different trades to become filled. The total cost received by the writing party (or parties) was $54.4K, with a price of $140.0 per contract. There were 2327 open contracts at this strike prior to today, and today 836 contract(s) were bought and sold.

    • For INCY (NASDAQ:INCY), we notice a call option trade that happens to be bearish, expiring in 17 day(s) on June 21, 2024. This event was a transfer of 500 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $57.5K, with a price of $115.0 per contract. There were 6331 open contracts at this strike prior to today, and today 664 contract(s) were bought and sold.

    • For ABT (NYSE:ABT), we notice a call option sweep that happens to be bullish, expiring in 73 day(s) on August 16, 2024. This event was a transfer of 336 contract(s) at a $110.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $43.0K, with a price of $128.0 per contract. There were 3029 open contracts at this strike prior to today, and today 362 contract(s) were bought and sold.

    • For NVAX (NASDAQ:NVAX), we notice a put option trade that happens to be bullish, expiring in 45 day(s) on July 19, 2024. This event was a transfer of 300 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $378.0K, with a price of $1260.0 per contract. There were 308 open contracts at this strike prior to today, and today 303 contract(s) were bought and sold.

    • For EXAS (NASDAQ:EXAS), we notice a put option sweep that happens to be bullish, expiring in 17 day(s) on June 21, 2024. This event was a transfer of 67 contract(s) at a $47.50 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $29.4K, with a price of $440.0 per contract. There were 1546 open contracts at this strike prior to today, and today 181 contract(s) were bought and sold.

    • Regarding BMRN (NASDAQ:BMRN), we observe a put option trade with bearish sentiment. It expires in 227 day(s) on January 17, 2025. Parties traded 66 contract(s) at a $75.00 strike. The total cost received by the writing party (or parties) was $32.3K, with a price of $490.0 per contract. There were 525 open contracts at this strike prior to today, and today 68 contract(s) were bought and sold.

    • For DXCM (NASDAQ:DXCM), we notice a put option trade that happens to be bullish, expiring in 199 day(s) on December 20, 2024. This event was a transfer of 32 contract(s) at a $115.00 strike. The total cost received by the writing party (or parties) was $33.9K, with a price of $1060.0 per contract. There were 20 open contracts at this strike prior to today, and today 32 contract(s) were bought and sold.

    • Regarding VKTX (NASDAQ:VKTX), we observe a call option sweep with bullish sentiment. It expires in 227 day(s) on January 17, 2025. Parties traded 22 contract(s) at a $30.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $66.0K, with a price of $3000.0 per contract. There were 1261 open contracts at this strike prior to today, and today 26 contract(s) were bought and sold.

    • Regarding BSX (NYSE:BSX), we observe a call option sweep with bullish sentiment. It expires in 17 day(s) on June 21, 2024. Parties traded 20 contract(s) at a $60.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $31.9K, with a price of $1599.0 per contract. There were 2846 open contracts at this strike prior to today, and today 20 contract(s) were bought and sold.

    Options Alert Terminology
    - Call Contracts: The right to buy shares as indicated in the contract.
    - Put Contracts: The right to sell shares as indicated in the contract.
    - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it.
    - Premium/Option Price: The price of the contract.

    For more information, visit our Guide to Understanding Options Alerts or read more news on unusual options activity.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABT
    $BMRN
    $BSX
    $CERE

    CompanyDatePrice TargetRatingAnalyst
    Incyte Corp.
    $INCY
    2/5/2026$135.00Buy
    H.C. Wainwright
    BioMarin Pharmaceutical Inc.
    $BMRN
    1/28/2026$80.00Overweight
    Barclays
    Incyte Corp.
    $INCY
    1/20/2026$107.00Overweight → Equal Weight
    Wells Fargo
    Exact Sciences Corporation
    $EXAS
    1/20/2026$105.00Outperform → Neutral
    Mizuho
    BioMarin Pharmaceutical Inc.
    $BMRN
    1/20/2026$98.00Hold → Buy
    Canaccord Genuity
    DexCom Inc.
    $DXCM
    1/12/2026$71.00Equal Weight → Underweight
    Barclays
    Exact Sciences Corporation
    $EXAS
    1/5/2026$105.00Outperform → In-line
    Evercore ISI
    Incyte Corp.
    $INCY
    12/8/2025$121.00Neutral → Outperform
    Mizuho
    More analyst ratings

    $ABT
    $BMRN
    $BSX
    $CERE
    SEC Filings

    View All

    Boston Scientific Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)

    2/23/26 4:33:54 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    BioMarin Pharmaceutical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)

    2/23/26 4:08:42 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Abbott Laboratories

    424B3 - ABBOTT LABORATORIES (0000001800) (Filer)

    2/23/26 9:31:03 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $BMRN
    $BSX
    $CERE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results

    Full-year 2025 Total Revenues Increased 13% Y/Y to $3.2 Billion, Led by 9% Revenue Growth for Enzyme Therapies and 26% Revenue Growth for VOXZOGO®Fourth Quarter 2025 Total Revenues Increased 17% Y/Y Led by 13% Revenue Growth for Enzyme Therapies and 31% Revenue Growth for VOXZOGOAnnounced Definitive Agreement to Acquire Amicus Therapeutics, including Galafold® for Fabry Disease and Pombiliti® + Opfolda® for Pompe Disease; Expected to Significantly Accelerate and Diversify RevenuesBioMarin Provides 2026 Guidance Excluding any Post-Close Contribution from the Announced Acquisition of Amicus, Anticipated to Close in Q2'26Conference Call and Webcast Scheduled Today at 4:30 p.m. ETSAN RAFAEL, Cal

    2/23/26 4:05:00 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Boston Scientific elects Cathy Smith and Christophe Weber to Board of Directors

    MARLBOROUGH, Mass., Feb. 23, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) announced today the election of Cathy Smith and Christophe Weber to its Board of Directors, effective February 18, 2026. Smith is a seasoned executive with deep expertise in finance, corporate strategy and operational excellence. She currently serves as chief financial officer of Starbucks. Previously, she held chief financial officer roles at Nordstrom, Bright Health, Target, Express Scripts and Walmart, supporting large, complex organizations through periods of significant growth. Smith

    2/23/26 8:00:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    LifeMD to Report Fourth Quarter 2025 Financial Results on March 9

    NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and 12 months ended December 31, 2025, after the close of the U.S. financial markets on March 9, 2026, and will host a conference call beginning at 4:30 p.m. Eastern time. Conference Call & Webcast Details Date:Monday, March 9thTime:4:30 p.m. Eastern timeToll-Free Dial-In:800-343-5172International Dial-In:203-518-9856Conference ID:LIFEMDLive & Archived Webcast:Link   About LifeMD, Inc. LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy ser

    2/23/26 8:00:00 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    $ABT
    $BMRN
    $BSX
    $CERE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

    For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

    9/3/24 2:26:49 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 30, 2024 - FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

    For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of

    8/30/24 2:26:48 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    March 1, 2024 - FDA Roundup: March 1, 2024

    For Immediate Release: March 01, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a letter of enforcement discretion for certain qualified health claims regarding the consumption of yogurt and the reduced risk of type 2 diabetes. The letter states that the FDA does not intend to object to the use of these claims, provide

    3/1/24 4:00:21 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $ABT
    $BMRN
    $BSX
    $CERE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Starks Daniel J bought $1,087,331 worth of Common shares without par value (10,000 units at $108.73), increasing direct ownership by 0.15% to 6,738,817 units (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    2/6/26 8:04:16 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHAIRMAN AND CEO Ford Robert B bought $2,013,967 worth of Common shares without par value (18,800 units at $107.13) (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    1/26/26 8:02:24 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & COO Leach Jacob Steven bought $1,001,702 worth of shares (18,200 units at $55.04), increasing direct ownership by 6% to 331,697 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    11/10/25 7:13:08 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $ABT
    $BMRN
    $BSX
    $CERE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Incyte with a new price target

    H.C. Wainwright initiated coverage of Incyte with a rating of Buy and set a new price target of $135.00

    2/5/26 6:58:02 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Barclays resumed coverage on BioMarin Pharmaceutical with a new price target

    Barclays resumed coverage of BioMarin Pharmaceutical with a rating of Overweight and set a new price target of $80.00

    1/28/26 7:15:50 AM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Incyte downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Incyte from Overweight to Equal Weight and set a new price target of $107.00

    1/20/26 9:09:45 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABT
    $BMRN
    $BSX
    $CERE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, R&D Cagnoni Pablo J exercised 18,668 shares at a strike of $61.59 and sold $1,883,788 worth of shares (18,668 units at $100.91) (SEC Form 4)

    4 - INCYTE CORP (0000879169) (Issuer)

    2/23/26 4:05:14 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    EVP and CFO Monson Jonathan covered exercise/tax liability with 1,698 shares and converted options into 3,814 shares, increasing direct ownership by 6% to 37,986 units (SEC Form 4)

    4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

    2/18/26 5:58:53 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    SVP, Chief HR Officer O'Sullivan Miriam covered exercise/tax liability with 820 shares and converted options into 2,702 shares, increasing direct ownership by 12% to 17,302 units (SEC Form 4)

    4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

    2/18/26 5:58:52 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $ABT
    $BMRN
    $BSX
    $CERE
    Financials

    Live finance-specific insights

    View All

    BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results

    Full-year 2025 Total Revenues Increased 13% Y/Y to $3.2 Billion, Led by 9% Revenue Growth for Enzyme Therapies and 26% Revenue Growth for VOXZOGO®Fourth Quarter 2025 Total Revenues Increased 17% Y/Y Led by 13% Revenue Growth for Enzyme Therapies and 31% Revenue Growth for VOXZOGOAnnounced Definitive Agreement to Acquire Amicus Therapeutics, including Galafold® for Fabry Disease and Pombiliti® + Opfolda® for Pompe Disease; Expected to Significantly Accelerate and Diversify RevenuesBioMarin Provides 2026 Guidance Excluding any Post-Close Contribution from the Announced Acquisition of Amicus, Anticipated to Close in Q2'26Conference Call and Webcast Scheduled Today at 4:30 p.m. ETSAN RAFAEL, Cal

    2/23/26 4:05:00 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeMD to Report Fourth Quarter 2025 Financial Results on March 9

    NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and 12 months ended December 31, 2025, after the close of the U.S. financial markets on March 9, 2026, and will host a conference call beginning at 4:30 p.m. Eastern time. Conference Call & Webcast Details Date:Monday, March 9thTime:4:30 p.m. Eastern timeToll-Free Dial-In:800-343-5172International Dial-In:203-518-9856Conference ID:LIFEMDLive & Archived Webcast:Link   About LifeMD, Inc. LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy ser

    2/23/26 8:00:00 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    Abbott declares 409th consecutive quarterly dividend

    ABBOTT PARK, Ill., Feb. 20, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share. This marks the 409th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable May 15, 2026, to shareholders of record at the close of business on April 15, 2026.Abbott has increased its dividend payout for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years.About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio o

    2/20/26 11:38:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $BMRN
    $BSX
    $CERE
    Leadership Updates

    Live Leadership Updates

    View All

    BioMarin Appoints Arpit Davé Chief Digital and Information Officer

    Mr. Davé Brings more than 20 Years of Experience in Creating Enterprise Value through Digital Transformation, Information Technology and Artificial Intelligence across the Biopharmaceutical Industry SAN RAFAEL, Calif., Jan. 12, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced it has appointed Arpit Davé as Executive Vice President, Chief Digital and Information Officer, a new position reporting directly to President and Chief Executive Officer Alexander Hardy. Mr. Davé will be responsible for reimagining and executing BioMarin's enterprise technology strategy, data science and digital transformation to help create value for patients, employees and shareholders.

    1/12/26 4:05:00 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer

    Experienced Industry Leader with More than Two Decades of Global Commercialization and Marketing Expertise SAN DIEGO, Jan. 7, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the appointment of Neil Aubuchon as chief commercial officer. Mr. Aubuchon brings more than two decades of biopharmaceutical industry experience spanning leadership roles across global commercial and marketing functions including focus within the cardiometabolic space.

    1/7/26 7:00:00 AM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $BMRN
    $BSX
    $CERE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Viking Therapeutics Inc.

    SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)

    11/14/24 4:30:54 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by LifeMD Inc.

    SC 13G/A - LifeMD, Inc. (0000948320) (Subject)

    11/14/24 10:42:44 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    SEC Form SC 13G filed by Exact Sciences Corporation

    SC 13G - EXACT SCIENCES CORP (0001124140) (Subject)

    11/13/24 2:58:53 PM ET
    $EXAS
    Medical Specialities
    Health Care